David Kellner, MD: With inflammatory arthritis, we know that obesity is associated with higher disease activity with more pain, worse function and, in some cases, even reduced response to certain biologic therapies
You need to track your progress and make adjustments throughout your treatment journey
Comparative analysis of GLP-1 receptor agonists, traditional glucose lowering medications and traditional anti obesity medications on skeletal outcomes in obese individuals with and without Type 2 diabetes: a 5 year propensity score matched cohort study. We get the title is a bit overwhelming, but the study was a good one
So can the oral 25 mg substitute the weekly 2.4 mg
Making small yet strategic menu changes that cater to GLP-1 diners will be a win for consumers
But its often the small , everyday actions that make the biggest difference